Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer By Ogkologos - April 16, 2026 215 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase III study in patients recruited through the PATCH and STAMPEDE-1 trial networks Source RELATED ARTICLESMORE FROM AUTHOR Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes MOST POPULAR Scientists uncover how incurable skin cancer resists treatment at the end... March 29, 2023 Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer April 7, 2026 FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... May 13, 2026 Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in... January 12, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer
